Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study. Lim S, Chung YE, Seo JH, Lee Y, et al. Gynecol Oncol 2025;204:165-173.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lim S, Chung YE, Seo JH, Lee Y, et al. Efficacy and safety of pembrolizumab with or without lenvatinib in recurrent uterine carcinosarcoma: a real-world single-center study. Gynecol Oncol 2025;204:165-173.
PMID: 41349346